ATE284220T1 - Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode - Google Patents

Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode

Info

Publication number
ATE284220T1
ATE284220T1 AT00901600T AT00901600T ATE284220T1 AT E284220 T1 ATE284220 T1 AT E284220T1 AT 00901600 T AT00901600 T AT 00901600T AT 00901600 T AT00901600 T AT 00901600T AT E284220 T1 ATE284220 T1 AT E284220T1
Authority
AT
Austria
Prior art keywords
composition containing
containing macrophages
antinifective
production
hematopoietic properties
Prior art date
Application number
AT00901600T
Other languages
English (en)
Inventor
Bernard Klein
Zhao Yang Lu
Jacques Bartholeyns
Original Assignee
Idm Immuno Designed Molecules
Chu Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idm Immuno Designed Molecules, Chu Montpellier filed Critical Idm Immuno Designed Molecules
Application granted granted Critical
Publication of ATE284220T1 publication Critical patent/ATE284220T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00901600T 1999-02-03 2000-01-27 Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode ATE284220T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99400239 1999-02-03
PCT/EP2000/000647 WO2000045827A1 (en) 1999-02-03 2000-01-27 Cell composition containing macrophages, presenting anti-infectious and hematopoietic properties, and a process for preparing the same

Publications (1)

Publication Number Publication Date
ATE284220T1 true ATE284220T1 (de) 2004-12-15

Family

ID=8241869

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00901600T ATE284220T1 (de) 1999-02-03 2000-01-27 Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode

Country Status (8)

Country Link
US (1) US6737051B1 (de)
EP (1) EP1150694B1 (de)
AT (1) ATE284220T1 (de)
AU (1) AU782937B2 (de)
CA (1) CA2361608A1 (de)
DE (1) DE60016567T2 (de)
ES (1) ES2233327T3 (de)
WO (1) WO2000045827A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040044300A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20040077985A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
WO2005014015A1 (en) * 2003-07-16 2005-02-17 I.D.M. Immuno-Designed Molecules Compositions containing macrophages and uses thereof
US7508684B2 (en) * 2006-08-18 2009-03-24 Research In Motion Limited Handheld electronic device including multi-compartment shielding container and associated methods
CA2711549C (en) 2008-01-08 2016-08-23 The University Of Queensland Method of producing a population of cells
GB201608806D0 (en) * 2016-05-19 2016-07-06 Immodulon Therapeutics Ltd Method
EP3487511A4 (de) * 2016-07-25 2020-04-01 Cellular Approaches, Inc. Autologe und allogene makrophagen und monozyten zur verwendung in therapeutischen verfahren

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282725C (en) * 1986-04-18 1991-04-09 Brian A. Naughton Process for replicating bone marrow in vitro and using the same
US5649904A (en) * 1988-10-07 1997-07-22 Sandoz Ltd. Method of treating cancer with a fully myeloablative regimen of chemotherapy, radiation or both
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5672346A (en) * 1992-07-27 1997-09-30 Indiana University Foundation Human stem cell compositions and methods
US6060052A (en) * 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US5861483A (en) * 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof

Also Published As

Publication number Publication date
WO2000045827A1 (en) 2000-08-10
US6737051B1 (en) 2004-05-18
DE60016567T2 (de) 2005-12-08
AU2293800A (en) 2000-08-25
EP1150694B1 (de) 2004-12-08
EP1150694A1 (de) 2001-11-07
AU782937B2 (en) 2005-09-08
DE60016567D1 (de) 2005-01-13
CA2361608A1 (en) 2000-08-10
ES2233327T3 (es) 2005-06-16

Similar Documents

Publication Publication Date Title
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
TR200200938T2 (tr) CCR5 modülatörleri olarak piperidinler
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
DE69636989D1 (de) Bioaktive lasttragende zusammensetzungen zum knochenverbund
MY119403A (en) Novel compounds with analgesic effect.
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
IL159637A (en) Preparations @ for use @ in medicine @ genes that contain and transform cd34 + cells
BR9910251A (pt) Estimulação hematopoiética
EA200500149A1 (ru) Тканевые протективные цитокины для защиты, восстановления и стимуляции реактивных клеток, тканей и органов
SE9803986D0 (sv) New compositions
ATE153853T1 (de) Stabile, orale und absorbierbare therapeutische zusammensetzungen von nadh und nadph
MY144292A (en) Method of reducing oral tissue inflammation using magnolia extract
SE9900961D0 (sv) Novel compounds
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
DE69531098D1 (de) Piperidine und pyrrolidine
MXPA05010402A (es) Oxido nitrico en el tratamiento de la inflamacion.
SE9802208D0 (sv) Novel compounds
EP1962843A4 (de) Verwendung von parp-1-hemmern
NZ329198A (en) Diaromatic propynyl or dienyl compounds
MY129001A (en) Treatment of emphysema using rar selective retinoid antagonists
ATE284220T1 (de) Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
AU2003215878A8 (en) Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
SE9802209D0 (sv) Novel compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties